Navigation Links
Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease

Phase 2 Clinical Trials Initiated

CRANBURY, N.J., March 21, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today that it will present positive results from its recently completed Phase 1 clinical studies of Plicera(TM) (isofagomine tartrate, AT2101) for Gaucher disease at the of Medical Genetics (ACMG) Annual Meeting on March 21-25 in Nashville, TN. The Phase 1 results show that Plicera was well-tolerated and that oral administration resulted in a significant elevation of target enzyme levels in healthy volunteers. Based on these results, Amicus announced today the initiation of two Phase 2 clinical trials of Plicera for Gaucher disease.

Plicera is designed to selectively bind to and stabilize GCase, the enzyme deficient in Gaucher disease. This deficiency leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease. Plicera facilitates proper trafficking of the enzyme to the lysosomes, the compartments in the cell where it is needed to break down glucocerebroside.

Phase 1 Plicera data being presented at ACMG

Two double-blind, placebo-controlled, dose escalation Phase 1 studies in healthy volunteers were completed. These studies were designed to evaluate the safety, tolerability and pharmacokinetics of Plicera. In the first study, 36 subjects received a single dose of one of five dose levels of Plicera. The second study was a multiple-dose study in which 18 subjects received one of three dose levels of Plicera once daily for 7 consecutive days. In both studies, Plicera was safe and well tolerated at all doses. There were no serious adverse events and no subjects withdrew or discontinued due to an adverse event. In the multiple-dose study, a dose-depend
'"/>




Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... March 20 Valor Medical, an emerging medical,device company ... human,implant of Neucrylate AN for treatment of cerebral aneurysms ... Tehran. The treatment was under the,guidance of a clinical ... Committee., Dr. Pakbaz stated that the patient,s aneurysm ...
... for more ... anticoagulation patients, INDIANAPOLIS, March ... meter training, equipment and supplies for all long-term,warfarin users who ... The change opens the door to greater convenience and,potentially fewer ...
Cached Medicine Technology:Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 2Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 3Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 4
(Date:7/9/2014)... French . By ... including brain structure and function, personality, life experiences and genetics, ... to develop binge drinking within the next two years. Impulsivity, ... as life events and a family history of drug use ... not the child had had a single drink at age ...
(Date:7/9/2014)... highlights, Brian Williams refreshing old school rap classics, and ... A University of Colorado Cancer Center study published in ... also allows researchers, journals, and health advocates to connect ... and prevention. , "No matter what field you,re in, ... around the world," says Chante Karimkhani, MD candidate in ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... study published in the scientific journal Nature Neuroscience ... researchers at Universit Laval, reveals that it is possible ... involves rekindling pain so that it can subsequently be ... alleviate chronic pain. , The researchers from the Faculty ... sant mentale de Qubec (IUSMQ) were inspired by previous ...
(Date:7/8/2014)... in Memory Restoration has been awarded up to $15 ... for a four -year project aiming to help brain-injured ... experts in neurosurgery, engineering, neurobiology, psychology and physics will ... prosthesis in the brain. , Memory is the process ... encode information, store it and retrieve it. Certain types ...
Breaking Medicine News(10 mins):Health News:What drives a child to abuse alcohol? 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3
... Will Set Key Industry Records, CARROLLTON, Texas, Sept. ... of medical imaging facilities, has,announced it has begun construction ... project, in Sherman, Texas, represents several,firsts of its kind. ... Texas, it is the first,joint venture between multiple hospitals ...
... and Wolf Haldenstein Obtain Third-Largest Settlement,in Securities Fraud ... PHILADELPHIA, Sept. 10 Judge Morris E.,Lasker of ... Massachusetts has,granted final approval of a $52.5 million ... against Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: ...
... provides evidence that noncoding RNAs and interactions between noncoding ... than was previously understood. The research, published by Cell ... Cell, may be useful for identifying tumor-specific signatures associated ... cells exhibit genetic alterations in oncogenes or tumor suppressor ...
... has been made by McMaster researchers about Fragile X ... one in 4,000 males and one in 6,000 females. ... associated with mental impairment. The affected gene (FMR1) leads ... the fragile X mental retardation protein (FMRP). , ...
... ... Conference, Majority of Students Polled Think Health Centers Need to Improve their ... ... 2007 Sexual Health Report Card, the second,annual ranking of sexual health resources at American colleges ...
... CITY, Calif., Sept. 10 Genomic,Health, Inc. (Nasdaq: ... studies that,support the use of quantitative real-time polymerase ... assay, for measuring the hormone,receptors, estrogen receptor (ER) ... A separate study identified multiple genes,including the 21 ...
Cached Medicine News:Health News:Fry Construction Selected for High-Profile Medical Imaging Project 2Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas 2Health News:Stem cell research produces a key discovery for Fragile X Syndrome 2Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 2Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 3Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 4Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 5Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 6Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 7Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 8Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 9Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 10Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 11Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 2Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 3Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 4
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... PVC. 2 eyes, oral. Marked with ... X-ray opaque line. Graduated. Single use. ... reduce kinking of the tube by ... adapts to the anatomical situation at ...
... Ruschelit® PVC. Murphy eye-oral. High volume/low ... Oral Cuffed Single use. For improved ... of the tube by incorporating a ... cuff. Thermosensitive Ruschelit® PVC adapts to ...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Medicine Products: